Anthropic is making biotech boasts, but scientists are wary of hype around ‘curing cancer’

Anthropic has been pushing is biotechnology projects in a bid to drive up its stock price, but scientists warn people need to be realistic. The AI giant has opened a biology lab in the Bay Area, bought two biotech startups — one for about $400 million in stock — and partnered with drugmakers including Bristol...

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.